Kringle Pharma, Inc. (4884.T)
JPY 865.0
(1.76%)
JPY 865.0
(1.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -888.76 Million JPY | -108.55% |
| 2022 | - JPY | -19.08% |
| 2021 | -299.67 Million JPY | -108.55% |
| 2020 | - JPY | 53.84% |
| 2019 | - JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -212.97 Million JPY | 0.0% |
| 2024 Q1 | -168.59 Million JPY | 38.54% |
| 2024 Q2 | -198.15 Million JPY | 100.0% |
| 2023 Q4 | -268.27 Million JPY | 12.2% |
| 2023 FY | - JPY | -108.55% |
| 2023 Q3 | -305.55 Million JPY | -94.04% |
| 2023 Q1 | -157.46 Million JPY | -265.71% |
| 2023 Q2 | -157.46 Million JPY | 0.0% |
| 2022 FY | - JPY | -19.08% |
| 2022 Q4 | -43.05 Million JPY | 0.0% |
| 2021 FY | - JPY | -108.55% |
| 2020 FY | - JPY | 53.84% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 192.763% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -82.074% |
| GNI Group Ltd. | 14.48 Billion JPY | 106.134% |
| Linical Co., Ltd. | 1.24 Billion JPY | 171.259% |
| Trans Genic Inc. | 240.95 Million JPY | 468.854% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 34.45% |
| Soiken Holdings Inc. | -583.2 Million JPY | -52.392% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -47.368% |
| AnGes, Inc. | -8.86 Billion JPY | 89.969% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 30.862% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 87.988% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 793.765% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -2.985% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 18.595% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1756.562% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -14.592% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -694.95% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 26.654% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 35.635% |
| PeptiDream Inc. | 7.37 Billion JPY | 112.049% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 53.943% |
| Ribomic Inc. | -1.01 Billion JPY | 12.223% |
| SanBio Company Limited | -4.52 Billion JPY | 80.359% |
| Healios K.K. | -3 Billion JPY | 70.444% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 23.763% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 36.201% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 36.608% |
| StemRIM | -2.03 Billion JPY | 56.262% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 168.029% |
| FunPep Company Limited | -952 Million JPY | 6.643% |
| Stella Pharma Corporation | -723.85 Million JPY | -22.782% |
| TMS Co., Ltd. | -937 Million JPY | 5.148% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -14.621% |
| Cuorips Inc. | -518 Million JPY | -71.576% |
| K Pharma,Inc. | 366.05 Million JPY | 342.793% |
| Takara Bio Inc. | 8.02 Billion JPY | 111.076% |
| ReproCELL Incorporated | 8.24 Million JPY | 10879.406% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1110.669% |
| StemCell Institute Inc. | 534.35 Million JPY | 266.325% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 463.036% |
| CellSeed Inc. | -836.51 Million JPY | -6.246% |